Established in 2017, Rejuvenate Biomed is a clinical-stage, privately held, platform and pipeline company dedicated to redefining the aging process. Their mission is to ensure lifelong health by developing innovative therapeutics that target the root causes of age-related diseases. Rejuvenate Biomed has established two distinct drug discovery platforms, AI-enabled in silico CombinAge and in vivo CelegAge. As a result, Rejuvenate Biomed has developed a pipeline of five unique combination drugs targeting various age-related diseases, including neuromuscular, musculoskeletal, metabolic, cardiovascular, nephrological, and neurodegenerative indications. Lead candidate RJx-01 is safe and well tolerated in a 6-week Phase 1b clinical trial in disuse-induced sarcopenia, with positive functional outcome data. These promising results support the progression to Phase 2 studies in sarcopenia and osteoporosis, marking a significant step forward in the commitment to promote healthy aging.